Clinical Trial Update: Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment [Phase 1, Phase 2]

View source ↗

Summary

Phase Ib/Phase II single-arm studies evaluating AZD6094 (Volitinib) with Docetaxel in solid cancers, and in advanced gastric adenocarcinoma with MET amplificati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastric Cancer

Drugs mentioned

• AZD6094 (Volitinib) (volitinib)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Samsung Medical Center | Conditions: Advanced Gastric Adenocarcinoma | Phase 1, Phase 2 | Status: COMPLETED